SUBSTITUTED PYRIMIDIN-4(3H)-ONES FOR USE IN TREATING CANCER

The present disclosure provides a method of treating cancer or a solid tumor (e.g., an advanced or metastatic solid tumor) in a subject with a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, conformational isomer, t...

Full description

Saved in:
Bibliographic Details
Main Authors SINKEVICIUS, Kerstin, WADE, Anna, WOOD, Lauren, DAMBKOWSKI, Carl, LIM, Justin, WALLACE, Eli, VAN VEENHUYZEN, David, WEN, Susanna, BELTRAN, Pedro
Format Patent
LanguageEnglish
Published 03.07.2025
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides a method of treating cancer or a solid tumor (e.g., an advanced or metastatic solid tumor) in a subject with a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, conformational isomer, tautomer, or a combination thereof, where the subject has one or more mutations in the MAPK pathway and/or one or more mutations in PTPN11. In particular, the solid tumor is an advanced or metastatic KRAS mutant solid tumor (e.g., KRAS G12C-positive solid tumor); an advanced or metastatic NF1 loss-of-function (LOF) solid tumor or BRAF class II/III mutant solid tumor; or chordoma.
Bibliography:Application Number: US202218698694